UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F | ☐ | REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 | | --- | --- | | | OR | | ☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For the fiscal year ended June 30, 2021 | | | OR | | ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | OR | | ☐ | SHELL COMPANY REPORT PURSUANT TO SECTION 13 ...

WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of even ...

Mesoblast Limited (NASDAQ:MESO) Q4 2020 Earnings Conference Call August 26, 2020 6:00 PM ET Company Participants Silviu Itescu - Chief Executive Officer and Managing Director Josh Muntner - Chief Financial Officer Fred Grossman - Chief Medical Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Jeffrey Cohen - Ladenburg Thalmann & Co. Inc. Tanushree Jain - Bell Potter Securities Jason Folger - Dawson James Securities Inc Swayampakula Ramakanth - H.C. Wainwright & Co., LLC Operator Hello, an ...

olast Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases Financial Year Ended June 30, 2020 ASX: MSB; Nasdaq: MESO CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, level ...

Mesoblast Ltd (NASDAQ:MESO) Q4 2020 Earnings Conference Call May 27, 2020 6:00 PM ET Corporate Participants Silviu Itescu - CEO Josh Muntner - CFO Fred Grossman - CMO Conference Call Participants Louise Chen - Cantor Jeffrey Cohen - Ladenburg Thalmann Jason Folger - Dawson James Securities Tanushree Jain - Bell Potter Securities Operator Hello, and welcome to the financial results for the period ended March 31, 2020, and corporate update for Mesoblast. An announcement and presentation has been lodged with t ...

Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases Financial and Operational Highlights for the Third Quarter Ended March 31, 2020 ASX: MSB; Nasdaq: MESO CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ ma ...

Mesoblast Limited (NASDAQ:MESO) Q2 2020 Earnings Conference Call February 26, 2020 4:30 PM ET Company Participants Silviu Itescu - Chief Executive Officer Josh Muntner - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Jason Kolbert - Dawson James Tanushree Jain - Bell Potter Securities Marc Sinatra - Lodge partners Operator Hello and welcome to Mesoblast???s Financial Results Webcast for the Six Months Ended December 31, 2019. An announcement and slide presentation have been lodged ...

Mesoblast Limited (NASDAQ:MESO) Q1 2020 Earnings Conference Call November 25, 2019 4:30 PM ET Company Participants Silviu Itescu - Chief Executive Officer and Managing Director Josh Muntner - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Jeffrey Cohen - Ladenburg Thalmann Tanushree Jain - Bell Potter Securities Operator Hello, and welcome to Mesoblast???s Financial Results Webcast for the Quarter Ended September 30, 2019. An announcement and slide presentation have bee ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F | | | OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission file num ...

blast Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases FY Ended June 30, 2019 Nasdaq: MESO ASX: MSB CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity ...